6-羟基-4-氧代-1,4-二氢-3-吡啶甲腈 | 146391-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-羟基-4-氧代-1,4-二氢-3-吡啶甲腈
• 英文名称: 4-hydroxy-6-oxo-1,6-dihydropyridine-3-carbonitrile
• 英文别名: 4,6-Dihydroxynicotinonitrile；4-hydroxy-6-oxo-1H-pyridine-3-carbonitrile
• CAS: 146391-91-5
• 化学式: C₆H₄N₂O₂
• mdl: MFCD08276123
• 分子量: 136.11
• InChiKey: YQAJUEYKLZAWPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  73.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-羟基-4-氧代-1,4-二氢-3-吡啶甲腈 、 4-溴苯甲砜 在 copper(l) iodide 、 4,7-二甲氧基-1,10-菲咯啉 potassium carbonate 、 盐酸 作用下， 以 二甲基亚砜 、 水 为溶剂， 以5.74%的产率得到4-hydroxy-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridine-3-carbonitrile
  参考文献：
  名称：

  PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

  摘要：

  提供了一些新的化合物，它们是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR 119 G蛋白偶联受体调节剂疗法的疾病方面非常有用。这些新的化合物具有结构式I或结构式IA。

  公开号：

  US20090023702A1

文献信息

• Thiazoline acid derivatives
  申请人：Bergeron J. Raymond

  公开号：US20070238767A1

  公开（公告）日：2007-10-11

  The present invention relates to novel thiazoline acids and derivatives thereof useful as chelators of trivalent metals in therapeutic applications. For example, the thiazoline acid derivatives are useful in diagnosing and treating pathological conditions associated with an excess of trivalent metals in humans and animals.

  本发明涉及一种新的噻唑啉酸及其衍生物，可用作治疗应用中三价金属的螯合剂。例如，噻唑啉酸衍生物在诊断和治疗与人类和动物中三价金属过量相关的病理状况方面是有用的。
• Pyridone GPR119 G protein-coupled receptor agonists
  申请人：Bristol-Myers Squibb Company

  公开号：US08003796B2

  公开（公告）日：2011-08-23

  Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.

  提供了新型化合物，其为GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂疗法的疾病方面具有用途。这些新型化合物具有结构式I或结构式IA。
• COMPOSITION, METHOD AND KIT FOR POTENTIATING ANTITUMOR ACTIVITY AND FOR CURING TUMOR
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：EP0543015A1

  公开（公告）日：1993-05-26

  A composition for potentiating the antitumor activity of tegafur and reducing the adverse effects, comprising a compound represented by general formula (I) wherein X represents halogen or cyano and oxonic acid or a pharmaceutically acceptable salt thereof, and a method and kit therefor; and a composition for curing tumors comprising tegafur, a compound represented by formula (I) and oxonic acid or a pharmaceutically acceptable salt thereof; and a method and kit therefor.

  一种用于增强替加氟抗肿瘤活性并减少不良反应的组合物，该组合物由通式（I）代表的化合物（其中 X 代表卤素或氰基）和氧杂酸或其药学上可接受的盐组成；以及一种用于治疗肿瘤的组合物，该组合物由替加氟、通式（I）代表的化合物和氧杂酸或其药学上可接受的盐；以及一种方法和试剂盒组成。
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF
  申请人：Chen, Xiaohua

  公开号：EP3563856A1

  公开（公告）日：2019-11-06

  The invention discloses a pharmaceutical composition for cancer treatment and the applications thereof. The pharmaceutical composition and a kit strengthen the anti-cancer effects of Capecitabine and reduce side effects. The pharmaceutical composition comprises an effective dose of Capecitabine with an anti-cancer effect, an effective dose of Gimeracil with an anti-cancer synergy, and an effective dose of Oteracil potassium capable of reducing side effects, and is used to treat cancers of mammals which are sensitive to 5-Fluorouracil.

  本发明公开了一种用于癌症治疗的药物组合物及其应用。该药物组合物和一种试剂盒可加强卡培他滨的抗癌效果并减少副作用。该药物组合物由具有抗癌作用的有效剂量的卡培他滨、具有抗癌增效作用的有效剂量的吉莫拉西和能够减少副作用的有效剂量的奥特拉西钾组成，用于治疗对5-氟尿嘧啶敏感的哺乳动物癌症。
• Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1<i>H</i>)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119
  作者：Dean A. Wacker、Ying Wang、Matthias Broekema、Karen Rossi、Steven O’Connor、Zhenqiu Hong、Ginger Wu、Sarah E. Malmstrom、Chen-Pin Hung、Linda LaMarre、Anjaneya Chimalakonda、Lisa Zhang、Li Xin、Hong Cai、Cuixia Chu、Stephanie Boehm、Jacob Zalaznick、Randolph Ponticiello、Larisa Sereda、Song-Ping Han、Rachel Zebo、Bradley Zinker、Chiuwa Emily Luk、Richard Wong、Gerry Everlof、Yi-Xin Li、Chunyu K. Wu、Michelle Lee、Steven Griffen、Keith J. Miller、John Krupinski、Jeffrey A. Robl

  DOI：10.1021/jm501175v

  日期：2014.9.25

  G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic beta-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. This dual mechanism of action has generated significant interest in the discovery of small molecule GPR119 agonists as a potential new treatment for type 2 diabetes. Herein, we describe the discovery and optimization of a new class of pyridone containing GPR119 agonists. The potent and selective BMS-903452 (42) was efficacious in both acute and chronic in vivo rodent models of diabetes. Dosing of 42 in a single ascending dose study in normal healthy humans showed a dose dependent increase in exposure and a trend toward increased total GLP-1 plasma levels.